Home
Conditions
Immune Checkpoint Inhibitors

Clinical trial condition

Immune Checkpoint Inhibitors

Explore clinical trials studying Immune Checkpoint Inhibitors. Study availability and eligibility vary by location and protocol.

29 public trials 10 recruiting studies

Refine in advanced search Browse all conditions

Immune Checkpoint Inhibitors trial results

Not yet recruiting

Phase II Trial of SFRT Plus Chemo-immunotherapy for LA-NSCLC With Suboptimal Neoadjuvant Response

NCT07670715

Conditions: Immune Checkpoint Inhibitors, Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Neoadjuvant Chemoimmunotherapy, +1 more
Locations: Tianjin Medical University Cancer Institute & Hospital Tianjin, Tianjin Municipality, China

View Trial Details

Not yet recruiting

Efficacy and Safety of Immune Checkpoint Inhibitors for Refractory Opportunistic Infections in AIDS

NCT07579247

Conditions: AIDS, Acquired Immunodeficiency Syndrome, Blood-Borne Infections, +18 more
Locations: Shanghai Public Health Clinical Center Shanghai, Shanghai Municipality, China

View Trial Details

Not yet recruiting

Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy

NCT07372079

Conditions: Breast Cancer, Breast Diseases, Breast Neoplasms, +7 more
Locations: Tianjin Medical University Cancer Institute & Hospital Tianjin, China

View Trial Details

Not yet recruiting

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

NCT07159217

Conditions: Biliary Tract Cancer, Biliary Tract Diseases, Biliary Tract Neoplasms, +7 more
Locations: Chinese Academy of Medical Sciences, Peking Union Medical College Hospital Beijing, China

View Trial Details

Not yet recruiting

Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer

NCT07132008

Conditions: Colonic Diseases, Colonic Neoplasms, Colorectal Neoplasms, +10 more
Locations: The First Affiliated Hospital of Guangxi Medical University Nanning, Guangxi, China

View Trial Details

Not yet recruiting

Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma

NCT06279403

Conditions: Clear-cell Metastatic Renal Cell Carcinoma, Clear-cell metastatic renal cell carcinoma, Cytoreductive Nephrectomy, +1 more
Locations: Not specified

View Trial Details

Not yet recruiting

Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma

NCT05898256

Conditions: Carcinoma, Head and Neck Neoplasms, Immune Checkpoint Inhibitors, +12 more
Locations: Not specified

View Trial Details

Active, not recruiting

Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population

NCT05863052

Conditions: Adenocarcinoma, Bronchial Neoplasms, Carcinoma, +46 more
Locations: Arizona Cancer Center at the Unvieristy of Arizona Tucson, Arizona, United States

University of New Mexico Comprehensive Cancer Center Albuquerque, New Mexico, United States

Stephenson Cancer Center Oklahoma City, Oklahoma, United States

Monument Health Cancer Care Institute Rapid City, South Dakota, United States

View Trial Details

Active, not recruiting

Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction

NCT06576921

Conditions: Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, +6 more
Locations: The fourth hospital of Hebei Medical University Shijiazhuang, Heibei Province, China

Department of Digestive surgery, Xijing Hospital of Digestive Diseases, Air Force Medical University, Xi' an, China Xi'an, Shaanxi, China

Department of General Surgery, Tangdu Hospital, Air Force Medical University Xi'an, Shaanxi, China

Department of General Surgery, The 986th Military Hospital, Air Force Medical University Xi'an, Shaanxi, China

View Trial Details

Active, not recruiting

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

NCT04572451

Conditions: Antineoplastic Agents, Antineoplastic Agents, Immunological, Immune Checkpoint Inhibitors, +15 more
Locations: University of Chicago Medical Center Chicago, Illinois, United States

UPMC Hillman Cancer Center Pittsburgh, Pennsylvania, United States

View Trial Details

Immune Checkpoint Inhibitors

Immune Checkpoint Inhibitors trial results

Related conditions